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Introduction {#sec001}
============

Lymph node count (LNC) is an important parameter of routine pathological report after resection of colorectal cancer (CRC) \[[@pone.0168156.ref001], [@pone.0168156.ref002]\]. Adequacy of lymph node assessment is usually required for accurate staging of patients with CRC \[[@pone.0168156.ref003], [@pone.0168156.ref004]\]. This goal has been simplified in clinical practice as a dedicated service of recovering more lymph nodes to meet a minimum requirement of 12 lymph nodes, as recommended by the American Joint Committee on Cancer (AJCC) and College of American Pathologists \[[@pone.0168156.ref005], [@pone.0168156.ref006]\]. Although many studies have demonstrated a correlation between increased LNC and prolonged survival in patients with CRC \[[@pone.0168156.ref007]--[@pone.0168156.ref011]\], the underlying mechanisms of LNC-associated survival advantage are still poorly understood \[[@pone.0168156.ref003], [@pone.0168156.ref012]\].

Several mechanisms have been proposed to explain LNC-related impact on survival. The most common mechanism is stage migration \[[@pone.0168156.ref007], [@pone.0168156.ref012], [@pone.0168156.ref013]\]. Theoretically, the likelihood of being under-staged and erroneously treated is reduced for patients with more lymph nodes recovered \[[@pone.0168156.ref007]\]. Accurate staging is essential for selection of appropriate therapy and maximization of survival benefit. However, recent studies suggest that increased LNC does not accompany with significant migration of pN stages \[[@pone.0168156.ref014], [@pone.0168156.ref015]\]. Another study also shows that pathological reevaluations for patients with less than 12 lymph nodes identified after initial assessment does not lead to marked increase in metastatic lymph nodes, lymph node ratio (LNR) or obvious migration of pN stages \[[@pone.0168156.ref016]\]. The second considered mechanism is extended lymphadenectomy \[[@pone.0168156.ref003], [@pone.0168156.ref012]\]. Complete mesocolic excision (CME) removes more lymph nodes, increasing the chance of eliminating skip metastasis and micrometastsis in lymph nodes at a longer distance from the primary tumor \[[@pone.0168156.ref012], [@pone.0168156.ref017]\]. A survival benefit for colon cancer patients after CME has been observed in several studies \[[@pone.0168156.ref017], [@pone.0168156.ref018]\], whilst conclusive evidence by clinical trials remains absent \[[@pone.0168156.ref019]\]. The third mechanism which exhibits appropriate rationality is that some predictors for increased lymph nodes are also independent factors for a survival advantage in CRC \[[@pone.0168156.ref003], [@pone.0168156.ref012]\]. For instance, younger age and microsatellite instable (MSI) phenotype are associated with more lymph nodes as well as better outcomes in CRC patients \[[@pone.0168156.ref020]--[@pone.0168156.ref022]\]. However, it is also reported that larger number of lymph node is more frequently observed in CRC with a greater diameter, poor histology, a proximal location and a deeper depth of penetration as well \[[@pone.0168156.ref003], [@pone.0168156.ref012], [@pone.0168156.ref013]\]. These factors tend to exert adverse rather than favorable effects on survival of patients with CRC \[[@pone.0168156.ref003], [@pone.0168156.ref023]\]. The contradiction indicates that the relationship between increased LNC and prolonged survival may be not straightforward as expected. Investigations on new responsible markers may help to understand the survival benefit.

Preoperative serum tumor markers and blood cell counts are routinely used to evaluate surgically-treated patients with CRC \[[@pone.0168156.ref003]\]. The relationship between them and LNC remains unclear. In this study, we retrospectively reviewed these preoperative parameters in addition to demographical and pathological characteristics of CRC patients who received curative surgery at the department of gastrointestinal surgery, Shanghai East Hospital. The first aim of the study is to identify potential clinical-pathological correlators for the benchmark of 12 lymph nodes in the Chinese population. The second aim is to develop and internal validate a nomogram to predict the possibility of inadequate lymph node recovery (LNC \< 12) before curative surgery. The study is expected to provide new traces for causative mechanisms that may explain associations between increased LNC and survival, and help to enable an adequate preoperative assessment, preparation and appropriate clinical decision for individualized therapy with the LNC-predictive nomogram.

Materials and Methods {#sec002}
=====================

Patients and variables {#sec003}
----------------------

Medical records of 690 consecutive patients with primary CRC, who received surgery with a curative intent at the department of gastrointestinal surgery of Shanghai East Hospital between August 2011 and June 2015, were retrospectively reviewed. Patients were considered for subsequent analysis based on the following exclusion criteria: (1) patient who underwent emergency surgeries (n = 6), (2) patients who received chemo-radiotherapy before blood tests and surgeries (n = 19), (3) pTis disease or multiple primaries (n = 13), (4) pathologically proven non-R0 resection (n = 8), and (5) patients with incomplete or inconsistent data to specify any used variables (n = 143).

Both preoperative and pathological variables were accessed for each patient. Preoperative variables included sex, age, white blood cell count (WBC, reference: 3.7--9.2 × 10^6^/mL), neutrophil count (NEU, reference: 2.0--7.0 × 10^6^/mL), lymphocyte count (LYM, reference: 0.8--4.0 × 10^6^/mL), platelet count (PLT, 10^6^/mL), hemoglobin concentration (Hb, g/L), serum carcinoembryonic antigen (CEA, reference: \< 5.2 ng/mL), CA19-9 (reference, \< 37 U/mL), CA50 (reference, \< 25 U/mL), CA72-4 (reference, \< 6.9 U/mL), type of surgery (open surgery or laparoscopy), tumor location and maximum diameter indicated by preoperative computed tomography scan. Pathological parameters assessed were experience of pathologist (junior or senior title), tumor macroscopy, grade, histology, vascular invasion, perineural invasion, LNC and tumor deposit in addition to tumor-node-metastasis classification by the 7th edition AJCC cancer stating manual. Presence of anemia was defined as a Hb concentration ≤ 110 g/L for females or 120 g/L for males. The normal upper limit of PLT used was 320 × 10^6^/mL for both sexes to define thrombocytosis. Laparoscopy was only implemented for patients who were appropriate and willing to receive it.

Statistical methods {#sec004}
-------------------

Continuous variables were compared with parametric or nonparametric methods depending on the distribution of the data. Discontinuous variables were compared using Chi-squared test or Fisher exact test. Concentrations of blood markers were pre-categorized to predict LNC ≥ 12 according to their normal references (i.e., for Hb and PLT) or optimal cut-off values determined by maximization of Yuden Index with receiver operating characteristic (ROC) curve analysis, based on clinical reasoning and significance. To identify correlative factors for LNC ≥ 12, significant variables in univariate logistic regression analysis were evaluated in multivariate logistic analysis with a stepwise forward elimination of insignificant variables using the PASW 18.0 program (SPSS, Chicago, IL). To identify predictors for LNC ≥ 12 that would be used in the nomogram, similar univariate and multivariate logistic analyses were performed using preoperative variables to derive a final variable formula. Nomogram was built in R program (v 3.2.3) with the *rms* package. Performance of the nomogram was assessed by concordance index (c-index) and the area under the ROC curve (AUC) with associated 95% confident interval (95% CI). Internal validation and calibration of the nomogram were conducted by 1000-resample bootstrapping. The ranges of threshold probability, between which the nomogram was clinically valid, were determined by decision curve analysis (DCA). After addressing model performance, each patient was given an aggregated point on the basis of the nomogram. The points of all patients were then divided into quartiles to investigate whether increased probability of adequate lymph node recovery had significant impact on diagnosis of nodal status as well as AJCC stages. Statistical significance of all tests was set as a two-sided *P* value \< 0.05.

The study data were extracted and analyzed in January of 2016 under the condition of anonymity, during which the researchers did not have the access to patient-identifying information. The study adhered to the Declaration of Helsinki for medical research involving human subjects \[[@pone.0168156.ref024]\] and the STROBE guidelines (Please refer to [S1 Table](#pone.0168156.s001){ref-type="supplementary-material"} for STROBE guidelines). Due to difficulties to be obtained retrospectively, informed consents from participants were waived upon the approval of the Ethics Committee of the Shanghai East Hospital (Study ID: 2015-LSD-070).

Results {#sec005}
=======

Characteristics of the patients {#sec006}
-------------------------------

A final set of 501 patients with CRC was selected. Related clinical-pathological characteristics were shown in [Table 1](#pone.0168156.t001){ref-type="table"}.

10.1371/journal.pone.0168156.t001

###### Characteristics of patients with colorectal cancer.

![](pone.0168156.t001){#pone.0168156.t001g}

                                                     Lymph node count               
  -------------------------------------------------- ------------------ ----------- ----------
  Preoperative variables                                                            
  Age, year                                                                         0.007
      Mean                                           69.6/66.8          ---         
      SD                                             10.4/11.3          ---         
  Sex                                                                               0.158
      Female                                         58/139             29.4/70.6   
      Male                                           108/196            35.5/64.5   
  CEA, ng/mL                                                                        0.034
      ≤ 4.4                                          73/181             28.7/71.3   
      \> 4.4                                         93/154             37.7/62.3   
  CA19-9, U/mL                                                                      0.028
      ≤ 6.7                                          29/88              24.8/75.2   
      \> 6.7                                         137/247            35.7/64.3   
  CA50, U/mL                                                                        0.077
      ≤ 8.9                                          122/220            35.7/64.3   
      \> 8.9                                         44/115             27.7/72.3   
  CA72-4, U/mL                                                                      0.086
      ≤ 1.2                                          45/68              39.8/60.2   
      \> 1.2                                         121/267            31.2/68.8   
  Lymphocyte count, 10^6^/mL                                                        0.035
      ≤ 1.2                                          30/89              25.2/74.8   
      \> 1.2                                         136/246            35.6/64.4   
  White blood cell count, 10^6^/mL                                                  0.191
      ≤ 6.7                                          112/206            35.2/64.8   
      \> 6.7                                         54/129             29.5/70.5   
  Neutrophils, 10^6^/mL                                                             0.018
      ≤ 2.2                                          6/32               15.8/84.2   
      \> 2.2                                         160/303            34.6/65.4   
  Anemia                                                                            \< 0.001
      No                                             51/163             23.8/76.2   
      Yes                                            115/172            40.1/59.9   
  Platelet, 10^6^/mL                                                                \< 0.001
      ≤ 320                                          157/267            37.0/63.0   
      \> 320                                         9/68               11.7/88.3   
  Location                                                                          0.003
      Proximal colon                                 35/117             23.0/77.0   
      Distal colon                                   53/74              41.7/58.3   
      Rectum                                         78/144             35.1/64.9   
  Diameter, cm                                                                      \< 0.001
      Mean                                           3.8/4.7            ---         
      SD                                             1.8/1.8            ---         
  Surgery                                                                           0.165
      Open                                           141/299            32.0/68.0   
      Laparoscopy                                    25/36              41.0/59.0   
  Pathological variables                                                            
  Pathologist                                                                       0.799
      Junior                                         24/59              28.9/71.1   
      Senior                                         142/276            34.0/66.0   
  Macroscopy                                                                        0.785
      Polypoid type                                  70/137             33.8/66.2   
      Ulcerative + Infiltrating type                 96/198             32.7/67.3   
  Differentiation                                                                   0.034
      G1+G2                                          137/248            35.6/64.4   
      G3+G4                                          29/87              25.0/75.0   
  Histology                                                                         \< 0.001
      Adenocarcinoma                                 159/285            35.8/64.2   
      Poorly differentiated + Mucous + Signet ring   7/50               12.3/87.7   
  Lymphovascular invasion                                                           0.775
      No                                             85/167             33.7/66.3   
      Yes                                            81/168             32.5/67.5   
  Perineural invasion                                                               0.239
      No                                             95/210             31.1/68.9   
      Yes                                            71/125             36.2/63.8   
  Deposit                                                                           \< 0.001
      No                                             122/305            28.6/71.4   
      Yes                                            44/30              59.5/40.5   
  pT stage                                                                          0.009
      T1                                             19/13              59.4/40.6   
      T2                                             29/58              33.3/66.7   
      T3                                             65/159             29.0/71.0   
      T4                                             53/105             33.5/66.5   
  PLNC                                                                              0.157
      Median                                         0/0                ---         
      IQR                                            0-1/0-2            ---         
  pN stage                                                                          0.081
      N0                                             90/180             33.3/66.7   
      N1                                             63/107             37.1/62.9   
      N2                                             13/48              21.3/78.7   
  Metastasis                                                                        0.572
      M0                                             155/317            32.8/67.2   
      M1                                             11/18              37.9/62.1   

Abbreviations: SD, standard deviation; CEA, carcinoembryonic antigen; PLNC, positive lymph node count; IQR, interquartile range.

Predictors for LNC ≥ 12 {#sec007}
-----------------------

Results of univariate logistic regression analysis were shown in [Table 2](#pone.0168156.t002){ref-type="table"}. Variables assessed in multivariate analysis and significant variables with associated odds ratio (OR) were shown in [Table 3](#pone.0168156.t003){ref-type="table"}. In the multivariate analysis (Model A in [Table 3](#pone.0168156.t003){ref-type="table"}) which adjusted both preoperative and pathological factors, patient age, CA19-9, LYM, NEU, PLT, tumor diameter, histology and tumor deposit emerged to be relatively important factors (*P* \< 0.05). A marginal effect was seen with respect to CEA, anemia and location of CRC (*P* \> 0.05 and *P* \< 0.1). In the multivariate analysis (Model B in [Table 3](#pone.0168156.t003){ref-type="table"}) which adjusted only preoperative factors, decreased age, CEA, CA19-9, NEU, proximal location, increased PLT and tumor diameter were associated with increased probability of LNC ≥ 12 with a more prominent predictive effect (*P* \< 0.05). These predictors were selected to establish the nomogram. Additionally, the effect of the presence of anemia remained marginal (*P* = 0.097).

10.1371/journal.pone.0168156.t002

###### Univariate logistic regression analysis.
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                                                     Univariate analysis   
  -------------------------------------------------- --------------------- ----------
  Preoperative variables                                                   
  Age, year                                          0.98 (0.96--0.99)     0.008
  Sex (Male v Female)                                0.76 (0.51--1.11)     0.158
  CEA (\> 4.4 v ≤ 4.4)                               0.67 (0.46--0.97)     0.035
  CA19-9 (\> 6.7 v ≤ 6.7)                            0.59 (0.37--0.95)     0.029
  CA50 (\> 8.9 v ≤ 8.9)                              1.45 (0.96--2.19)     0.077
  CA72-4 (\> 1.2 v ≤ 1.2)                            1.46 (0.95--2.25)     0.087
  Lymphocyte count (\> 1.2 v ≤ 1.2)                  0.61 (0.38--0.97)     0.037
  White blood cell count (\> 6.7 v ≤ 6.7)            1.30 (0.88--1.92)     0.191
  Neutrophils (\> 2.2 v ≤ 2.2)                       0.36 (0.15--0.87)     0.023
  Anemia (Yes v No)                                  0.47 (0.32--0.69)     \< 0.001
  Platelet (\> 320 v ≤ 320)                          4.44 (2.16--9.15)     \< 0.001
  Location (referent = Proximal colon)                                     
      Distal colon                                   0.42 (0.25--0.70)     0.001
      Rectum                                         0.55 (0.35--0.88)     0.013
  Diameter, cm                                       1.37 (1.21--1.55)     \< 0.001
  Surgery (Laparoscopy v Open)                       0.68 (0.39--1.17)     0.166
  Pathological variables                                                   
  Pathologist (Senior v Junior)                      0.79 (0.47--1.32)     0.372
  Macroscopy (referent = Polypoid type)                                    
      Ulcerative + Infiltrating type                 1.05 (0.72--1.54)     0.785
  Differentiation (referent = G1+G2)                                       
      G3+G4                                          1.66 (1.04--2.65)     0.035
  Histology (referent = Adenocarcinoma)                                    
      Poorly differentiated + Mucous + Signet ring   3.98 (1.76--9.00)     0.001
  Lymphovascular invasion (Yes v No)                 1.06 (0.73--1.53)     0.775
  Perineural invasion (Yes v No)                     0.80 (0.55--1.16)     0.239
  Deposit (Yes v No)                                 0.27 (0.16--0.45)     \< 0.001
  pT stage (referent = T1)                                                 
      T2                                             2.92 (1.27--6.73)     0.012
      T3                                             3.58 (1.67--7.66)     0.001
      T4                                             2.90 (1.33--6.31)     0.007
  pN stage (referent = N0)                                                 
      N1                                             0.85 (0.57--1.27)     0.424
      N2                                             1.85 (0.95--3.58)     0.070
  Metastasis (M1 v M0)                               0.80 (0.37--1.74)     0.572

Abbreviations: LNC, lymph node count; CEA, carcinoembryonic antigen; OR, odds ratio; 95% CI, 95% confident interval.

10.1371/journal.pone.0168156.t003

###### Multivariate logistic regression analysis.
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                                                     Multivariate Model A   Multivariate Model B                       
  -------------------------------------------------- ---------------------- ---------------------- ------------------- ----------
  Preoperative variables                                                                                               
  Age, year                                          0.98 (0.96--0.99)      0.019                  0.98 (0.96--0.99)   0.012
  CEA (\> 4.4 v ≤ 4.4)                               ---                    0.062                  0.64 (0.42--0.97)   0.036
  CA19-9 (\> 6.7 v ≤ 6.7)                            0.53 (0.32--0.89)      0.017                  0.56 (0.34--0.93)   0.025
  Lymphocyte count (\> 1.2 v ≤ 1.2)                  0.52 (0.31--0.88)      0.015                  ---                 0.071
  Neutrophils (\> 2.2 v ≤ 2.2)                       0.29 (0.11--0.76)      0.012                  0.25 (0.10--0.62)   0.003
  Anemia (Yes v No)                                  ---                    0.067                  ---                 0.097
  Platelet (\> 320 v ≤ 320)                          3.58 (1.63--7.88)      0.002                  3.26 (1.50--7.08)   0.003
  Location (referent = Proximal colon)                                      0.056                                      0.034
      Distal colon                                   ---                    0.020                  0.47 (0.27--0.83)   0.009
      Rectum                                         ---                    0.385                  0.67 (0.40--1.11)   0.122
  Diameter, cm                                       1.37 (1.19--1.58)      \< 0.001               1.38 (1.20--1.59)   \< 0.001
  Pathological variables                                                                                               
  Differentiation (referent = G1+G2)                                                                                   
      G3+G4                                          ---                    0.402                  ---                 ---
  Histology (referent = Adenocarcinoma)                                                                                
      Poorly differentiated + Mucous + Signet ring   3.42 (1.40--8.31)      0.007                  ---                 ---
  Deposit (Yes v No)                                 0.23 (0.13--0.42)      \< 0.001               ---                 ---
  pT stage (referent = T1)                                                  0.412                                      
      T2                                             ---                    0.740                  ---                 ---
      T3                                             ---                    0.857                  ---                 ---
      T4                                             ---                    0.347                  ---                 ---

Abbreviations: LNC, lymph node count; CEA, carcinoembryonic antigen; OR, odds ratio; 95% CI, 95% confident interval.

Development of nomogram {#sec008}
-----------------------

The nomogram to predict the probability of LNC ≥ 12 for CRC patients before surgery was shown in [Fig 1](#pone.0168156.g001){ref-type="fig"}.

![Nomogram to predict LNC \> 11 before surgery.\
CEA, carcinoembryonic antigen; NEU, neutrophils; PLT, platelets.](pone.0168156.g001){#pone.0168156.g001}

Performance of nomogram {#sec009}
-----------------------

The c-index of the nomogram was 0.75 and 0.73 before and after correction for overfitting. The bootstrap calibration plot ([Fig 2A](#pone.0168156.g002){ref-type="fig"}) indicated a good agreement between nomogram-predicted and observed probability of adequate lymph node recovery. Moreover, the AUC of nomogram to predict LNC ≥ 12 was 0.75 (95% CI, 0.70--0.79), as estimated by the ROC curve analysis using nomogram-derived total points of patients as a predictive variable ([Fig 2B](#pone.0168156.g002){ref-type="fig"}). The results of DCA ([Fig 3](#pone.0168156.g003){ref-type="fig"}) suggested that the nomogram was clinically valid within probability thresholds between 10% and 60% when predicting the probability of failure to adequate lymph node recovery.

![**(A) Calibration plot and (B) receiver operating characteristic (ROC) curve analysis.** LNC, lymph node count; AUC, the area under the ROC curve; 95% CI, 95% confident interval.](pone.0168156.g002){#pone.0168156.g002}

![Decision curve analysis of the nomogram.\
LNC, lymph node count.](pone.0168156.g003){#pone.0168156.g003}

Impact of increased probability of adequate lymph node recovery {#sec010}
---------------------------------------------------------------

Four subgroups were classified by dividing the nomogram-derived total scores of all patients into quartiles. The probability of adequate lymph node recovery significantly corrected with score quartiles. Compared with the 1st quartile, the highest odds ratio (OR) to predict the probability was associated with the 4th quartile (OR = 14.48, 95% CI = 7.35 to 28.54, *P* \< 0.001), and the odds ratios were less dominant for the 2nd (OR = 2.79, 95% CI = 1.67 to 4.65, *P* \< 0.001) and the 3rd (OR = 6.10, 95% CI = 3.49 to 10.66, *P* \< 0.001) quartiles.

Further comparisons using violin plots ([Fig 4A--4D](#pone.0168156.g004){ref-type="fig"}) revealed that increased probability of adequate lymph node recovery before surgery was associated with increased LNC and negative lymph node count (NLNC) (both *P* values for Kruskal-Wallis test \< 0.001); however it did not correlated with increased positive lymph node count (PLNC) or increased lymph node ratio (LNR) (*P* values for one-Way Anova were 0.448 and 0.500). Additional assessments with proportional stacked bar charts ([Fig 4E--4H](#pone.0168156.g004){ref-type="fig"}) indicated that the increased probability of adequate lymph node recovery before surgery was well correlative with adequate lymph node recovery after resection of CRC (*P* \< 0.001). The increased probability also showed an association with deeper infiltration (*P* = 0.004) but did not lead to apparent migrations of the pN (*P* = 0.856) or AJCC stages (*P* = 0.089).

![Violin plots and proportional stacked bar charts.\
(A) lymph node count (LNC), (B) negative lymph node count (NLNC), (C) positive lymph node count (PLNC), (D) lymph node ratio (LNR), (E) LNC, (F) pT stages, (G) pN stages, (H) American Joint Committee on Cancer (AJCC) stages.](pone.0168156.g004){#pone.0168156.g004}

Discussion {#sec011}
==========

In the current study, we retrospectively identified a number of predictors for adequate lymph node recovery through univariate and multivariate logistic analyses. We also developed and internally validated a preoperative nomogram, which incorporated several operator-independent markers and achieved a moderate predictive accuracy. In addition, we demonstrated with the nomogram that increased probability of adequate lymph node recovery before surgery was associated with increased LNC and NLNC during pathological assessment but it did not lead to significant changes in PLNC, LNR, pN stages or AJCC stages.

Previous researches have investigated and identified numerous clinical-pathological factors that significantly correlate with LNC. The spectrum of related variables in patients with CRC is generally wide, which includes patient-related, tumor-specific, technique-dependent and hospital-varying factors \[[@pone.0168156.ref008]--[@pone.0168156.ref014]\]. In the study, we reproduced similar results for some conventionally relevant and irrelevant markers such as age, tumor location, diameter, histology, type of surgery and pathologist \[[@pone.0168156.ref012], [@pone.0168156.ref013], [@pone.0168156.ref025]--[@pone.0168156.ref027]\]. The related mechanisms have been well explained in some tailored reviews \[[@pone.0168156.ref012], [@pone.0168156.ref013]\]. We also identified some unreported biomarkers that might be inexpensive predictors for adequate lymph node recovery before surgery.

First of all, the results of multivariate analysis agree with the consensus that the recovery of lymph node may be multifactorial. However, the significant correlation with circulating markers is inconsistent with the consideration of using LNC as an indicator for surgical or pathological quality. According to the latest NCCN guideline \[[@pone.0168156.ref003]\], adjuvant therapy is no longer recommended for T3N0M0 colon cancer with a MSI phenotype irrespective of the presence of any high-risk features including a LNC \< 12. This update is based on clinical trials showing that stage II MSI patients have good prognosis and do not benefit from 5-FU adjuvant therapy \[[@pone.0168156.ref003]\]. Some pathological comparisons show that MSI CRCs are frequently present in patients with a younger age and a proximal location \[[@pone.0168156.ref028], [@pone.0168156.ref029]\], both of which were also associated with increased LNC in our study. MSI CRCs tend to represent poor differentiation due to a higher prevalence of mixed phenotypes and dominant mucinous morphology \[[@pone.0168156.ref028]\], a marker for increased LNC implicated by our results as well. Importantly, MSI CRCs induces more prominent lymphocytic reactions with an increased density of cytotoxic T cells which are responsible for antitumor immunity and elimination of metastasis in lymph nodes \[[@pone.0168156.ref028], [@pone.0168156.ref030]\]. The study by Ogino and colleagues also demonstrates that increased lymphocytic reaction score is not only associated with MSI CRC but also concurrently associated with increased NLNC and a tendency of increased LNC \[[@pone.0168156.ref029]\]. The effects of lymphocytic reactions to CRC partially explain the good prognosis of MSI CRC and may simultaneously serve as a mechanism of the association between increased LNC and prolonged survival. These findings suggest that LNC may be an indicator of lymphocytic reaction to CRC; meanwhile, the factors that correlate with a higher LNC are also involved in enhanced lymphocytic reaction. Secondly, a negative association between CEA, CA19-9, circulating neutrophils, lymphocytes and LNC was identified by our analyses. The relationship between CEA, CA19-9 and LNC may be explained as a reflection of the antagonistic balance between tumor expansion and host immunity such as lymphocytic reactions. Peripheral neutrophils and neutrophil to lymphocyte ratio (NLR) are classic markers for systemic inflammatory response (SIR) which is usually measured by modified Glasgow Prognostic Score (mGPS) \[[@pone.0168156.ref031]\]. Interleukin-6 gets involved in multiple processes during SIR, i.e., by inducing production of acute-phase proteins, proliferation of neutrophils and differentiation of megakaryocyte to platelets \[[@pone.0168156.ref032], [@pone.0168156.ref033]\]. Activated SIR interrelates increased c-reactive protein, circulating neutrophils, NLR, mGPS, IL-6, platelets, tumor necrosis and decreased albumin, lymphocytes, hemoglobin, peritumoral infiltrate, and of course poorer survival \[[@pone.0168156.ref032]--[@pone.0168156.ref035]\]. It is in accordance with a recent study which verifies that increased Foxp3^+^ tumor infiltrating lymphocytes are related to increased serum albumin and better outcomes in stage II and III CRC \[[@pone.0168156.ref036]\]. This also seems to be consistent with another study which finds that reduced LNC is linked to colon cancer patients with activated SIR \[[@pone.0168156.ref037]\]. But due to a lack of multivariate analysis, the conclusion in the study needs further validation. Our study displayed that LNC might positively correlated with platelet count. A plausible explanation is that the differentiation of megakaryocyte to platelets can be induced by tumor cells through secretion of vascular endothelial cell growth factor (VEGF) \[[@pone.0168156.ref038]\]. This is confirmed by another research which clarified significant associations between increased platelets and increased tumor diameter, younger age as well as higher pT stages \[[@pone.0168156.ref039]\]. All of the latter three variables are markers of increased LNC. With respect to lymphocyte count, we only observed a borderline association with LNC. The result may reflect either the heterogeneity of circulating lymphocytes or the less prominent importance relative to other covariates. Further studies on subpopulations of lymphocytes in the bloodstream and tumor draining lymph nodes may provide potential mechanisms between circulating, infiltrating lymphocytes and LNC \[[@pone.0168156.ref040], [@pone.0168156.ref041]\]. As for tumor deposit, its inverse relationship with LNC demonstrated in our study supports the view that metastases in the deposits and the lymph nodes are different entities, and this relationship may offer an additional reason for LNC-related survival advantage and favor the rationality of a separated N1c stage for the presence of the tumor deposit. Lastly, our nomogram was developed to preoperatively assess the probability of adequate lymph node recovery following standard surgical and pathological procedures. It is intriguing that the nomogram-predicted probability exhibited good correlation with both increased LNC and NLNC but neither PLNC nor LNR. In theory, removal of NLNC is not pathologically consequential, whilst increased NLNC has been proposed as an independent predictor for improved survival of patients with CRC \[[@pone.0168156.ref042]\]. Obviously, micrometastasis in pN0 patients should be a responsible mechanism because it is not a rare event. Marked regional lymphocytic reaction to CRC leads to better survival with increased LNC and NLNC as indictors, thus it may be another reason for survival advantage with NLNC. In addition, the data did not support significant stage migrations by increased LNC.

Our study has some limitations that allow us to interpret with caution. The research data were retrospectively collected and processed, during which the influence of selection bias might be underestimated. The cut-off values of circulating markers such as neutrophils and lymphocytes might be suboptimal due to a relatively small study population. Although the nomogram performed well in derivation cohort and remained stable during internal validation, it still needs independent external validation and attentions should be paid to the clinical validity of the nomogram during the external validation. Incorporation of new markers such as circulating tumor cells and cell-free DNAs may further promote the performance of the nomogram.

Conclusions {#sec012}
===========

In summary, the results of the study conclude some inexpensive and useful circulating markers that are capable of predicting the probability of adequate lymph node recovery before resection of CRC. The nomogram on the basis of the biomarkers exhibits promising performance that may allow for future validation and application in clinical practice. The identified predictors for LNC may also offer a number of new explanations of the association between increased LNC and prolonged survival. These explanations may involve the MSI phenotype, regional lymphocytic reaction, SIR, micrometastasis and host-tumor interactions under the background of cytokine imbalance. Moreover, it is likely that enhanced lymphocytic reactions are associated with improved survival by eliminating metastasis in lymph nodes and result in the increase of identifiable LNC and NLNC simultaneously. Although some studies have demonstrated that the prognostic value of LNR in CRC is superior to that of LNC, combination of LNC and LNR may achieve more prominent prognostic significance considering they are independent with each other. Next, the nomogram itself indicates that LNC is predictable. Under the context of homogeneous surgical procedures and pathological manipulations, the LNC retrieved from patients may mainly reflect patient-specific factors such as antitumor immunity and age at diagnosis rather than type of surgery or quality of pathologist. However, our study still supports a LNC ≥ 12 to be the benchmark for surgically-treated patients with CRC; because the benchmark remains evidence-based and is helpful for the standardization of surgical and pathological procedures. Eventually, the nomogram still needs external validation. Inclusion of circulating markers relating to SIR, antitumor immune response and tumor burdens may be directions of future studies.
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